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Microglia and astrocytes play essential roles in the
maintenance of homeostasis within the central
nervous system, but mechanisms that control the
magnitude and duration of responses to infection
and injury remainpoorlyunderstood.Here,weprovide
evidence that 5-androsten-3b,17b-diol (ADIOL) func-
tions as a selective modulator of estrogen receptor
(ER)b to suppress inflammatory responses of micro-
glia and astrocytes. ADIOL and a subset of synthetic
ERb-specific ligands, but not 17b-estradiol, mediate
recruitment of CtBP corepressor complexes to AP-
1-dependent promoters, thereby repressing genes
that amplify inflammatory responses and activate
Th17 T cells. Reduction of ADIOL or ERb expression
results in exaggerated inflammatory responses to
TLR4 agonists. Conversely, the administration of
ADIOL or synthetic ERb-specific ligands that promote
CtBP recruitment prevents experimental autoimmune
encephalomyelitis in an ERb-dependent manner.
These findings provide evidence for an ADIOL/ERb/
CtBP-transrepression pathway that regulates inflam-
matory responses in microglia and can be targeted
by selective ERbmodulators.INTRODUCTION
Microglia are resident myeloid-lineage cells in the parenchyma of
the central nervous system (CNS) that play essential roles in the
maintenanceofhomeostasisand responses to infectionand injury
(Glasset al., 2010;Ransohoff andPerry, 2009;Streit, 2002).Under
normal conditions, microglia are maintained in a quiescent state
by neuron and astrocyte-derived factors (Cardona et al., 2006),
and constantly survey the surrounding environment through an
extensive array of ramified processes (Nimmerjahn et al., 2005).
Upon detection of microbial invasion or evidence of tissue
damage, microglia rapidly initiate an inflammatory response that584 Cell 145, 584–595, May 13, 2011 ª2011 Elsevier Inc.serves to recruit the immune system and tissue repair processes.
Microglia sense infection and injury through numerous pattern
recognition receptors, such as toll-like receptors (TLR), that
regulate the activities of NF-kB, AP-1 and other signal-dependent
transcription factors (Akira et al., 2006). These transcription
factors act in a combinatorial manner to induce a robust program
of gene expression that initiates innate and adaptive immune
responses (Vallabhapurapu and Karin, 2009). Astrocytes also
sense infection and injury, and amplify the immune reaction initi-
ated by microglia (Saijo et al., 2009; Sofroniew and Vinters,
2010). Microglia/astrocyte activation is required for effective
immune responses, but the inflammatory program that is induced
by thesecells also has the potential to causeneuronal dysfunction
and death if inflammatory responses are not properly resolved.
Deregulation of inflammatory responses by microglia and astro-
cytes has been suggested to contribute to the severity of several
neurodegenerative diseases, including Parkinson’s disease,
Amyotrophic Lateral Sclerosis, Alzheimer’s disease, HIV-associ-
ated dementia and Multiple Sclerosis (MS) (Glass et al., 2010;
Perry et al., 2010; Yadav and Collman, 2009; Tiwari-Woodruff
et al., 2007).
Estrogens and synthetic estrogen receptor (ER) ligands have
been documented to exert anti-inflammatory effects in animal
models for MS (Gold and Voskuhl, 2009; Glass and Saijo, 2010),
suggesting that estrogen receptors may participate in physiolog-
ical regulation of inflammation. Roles of estrogens and their
receptors in the brain are particularly complex. Two members
of the nuclear receptor superfamily, estrogen receptor (ER),
ERa (NR3A1) andERb (NR3A2), bind to17b-estradiol andactivate
estrogen-regulated target genes (Kuiper et al., 1996; Chang et al.,
2008). ERa is highly expressed in female reproductive organs and
plays major roles in mediating the reproductive and sexually
dimorphic effects of estrogens in females. ERb also regulates
reproductive functions, but exhibits a distinct pattern of expres-
sion. Both ERb and ERa are expressed in the brain, with differen-
tial levels of expression observed in specific regions (Kuiper et al.,
1997; Laflamme et al., 1998). The relative expression levels and
functions of ERa and ERb in specific subsets of microglia, astro-
cytes and neurons have not been established.
Although theDNAbinding domains (DBDs) of ERa and ERb are
highly conserved (98% identity in human), their ligand-binding
domains (LBDs) exhibit less conservation (59% identity in
human), and ERb binds selectively a distinct spectrum of natu-
rally occurring as well as synthetic and plant-derived steroids
(Kuiper et al., 1997). Consistent with this, it has been possible
to develop synthetic ligands that exhibit preferential affinity for
ERa or ERb (Minutolo et al., 2009). Anti-inflammatory effects of
estrogens and ER-selective ligands within the CNS have been
extensively evaluated in the context of experimental autoim-
mune encephalomyelitis (EAE), an animal model of MS (Gold
and Voskuhl, 2009; Tiwari-Woodruff et al., 2007; Vegeto et al.,
2000). Therapeutic mechanisms include anti-inflammatory
effects in antigen presenting cells as well as neurotrophic
effects. Estrogen represses several proinflammatory mediators
including cytokines, chemokines, and matrix metalloprotei-
nase-9 in dendritic cells (Gold et al., 2009) and in microglia (Ve-
geto et al., 2000). The protective effect of estrogen requires ERa,
since it is not observed in ERa knockout mice (Gold and Voskuhl,
2009). However, treatment with the ERb-selective ligand 2,3-bis
(4-hydroxy-phenyl)-propionitrile (DPN) was also recently shown
to be protective in the EAE model (Tiwari-Woodruff et al.,
2007). This effect was not associated with anti-inflammatory
activity, but rather was proposed to be due to ERb ligands acting
on neurons to promote survival and preserve myelination.
Here, we report that synthetic ERb-specific ligands based
on a halogen-substituted phenyl-2H-indazole core (referred to
hereafter as Indazole-Br and Indazole-Cl) (De Angelis et al.,
2005) potently inhibit transcriptional activation of inflammatory
response genes in microglia and astrocytes. This observation
led to the identification of an ERb-specific transrepression
pathway that we propose is controlled endogenously by
regulated production of 5-androsten-3b,17b-diol (ADIOL).
17b -hydroxysteroid dehydrogenase type 14 (HSD17B14),
a member of HSD17B-family, converts 5- androsten-3b-ol-17-
one (dehydroepiandrosterone, DHEA) to ADIOL, and the expres-
sion of HSD17B14 itself is controlled by inducers and inhibitors
of inflammatory responses. Lack of this enzyme or ERb results
in exaggerated inflammatory responses in microglia and astro-
cytes. These findings suggest that an ADIOL-ERb-CtBP repres-
sion pathway may play roles in the maintenance of CNS homeo-
stasis by regulating the magnitude and duration of inflammatory
responses.
RESULTS
A Subset of ERb-Specific Ligands Inhibit Inflammatory
Responses in Microglia
Quantitative analysis of nuclear receptor expression in primary
mouse and human microglia indicated high levels of ERb tran-
scripts and relatively low levels of ERa transcripts (Figures S1A
and S1B available online). The murine BV2 microglia cell line
selectively expressed ERb (Figure S1C), in agreement with
a previous report (Baker et al., 2004). Taking advantage of BV2
cells, we first tested several ERb-specific synthetic ligands for
their effects on LPS-dependent activation of the inducible nitric
oxide synthase (iNOS) gene. Notably Indazole-Br and Indazole-
Cl (Figure S1D) (De Angelis et al., 2005) significantly repressed
the induction of iNOS mRNA, while 17b-estradiol (E2), the
ERa selective agonist 4,4’,4’’-(4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol (PPT) (Stauffer et al., 2000), and the structurally
distinct ERb-specific ligands DPN (Meyers et al., 2001) and
ERB-041 (Malamas et al., 2004) did not (Figure 1A). Knockdown
of ERb expression using a specific small inhibitory RNA (siRNA)
abolished the Indazole-Cl-mediated repression of iNOS mRNA
expression upon LPS stimulation (Figure 1B and Figure S1E).
In addition, Indazoles did not repress LPS-induced iNOS expres-
sion in mouse RAW264.7 macrophages that selectively express
ERa (Figures S1C and S1F). These results indicate that Indazole-
Br- and Indazole-Cl-mediated repression is ERb-dependent.
Several lines of evidence suggest that Th17 T cells play essen-
tial roles in focal autoimmune diseases including MS (Korn et al.,
2009; Littman and Rudensky, 2010). The differentiation and acti-
vation of Th17 T cells requires specific combinations of cyto-
kines provided by antigen presenting cells such as Transforming
growth factor (TGF)b, interleukin (IL)-6, IL-1b and IL-23 for mice
(Ghoreschi et al., 2010; Korn et al., 2009; Littman and Rudensky,
2010). Since microglia have been suggested to perform an
essential role in the onset of EAE (Heppner et al., 2005) and
estrogen played important roles to modify MS/EAE (Gold and
Voskuhl, 2009; Vegeto et al., 2008), we tested whether Inda-
zole-Br and Indazole-Cl could repress those cytokines required
for the differentiation and activation of Th17 T cells. In BV2 cells,
Indazole-Br and Indazole-Cl significantly repressed the mRNA
expression of IL-23p19 (Figure 1C), IL-6 (Figure 1D), and IL-1b
(Figure 1E) that are required for the differentiation and activation
of Th17 T cells, but not TGFb, which is important also for the
differentiation of anti-inflammatory regulatory T cells (Tregs) (Fig-
ure 1F) (Littman and Rudensky, 2010). Indazole-Cl repressed
IL-6 expression with an EC50 value of 30-100 nM in BV2 cells
(Figure S1G). Similarly, Indazole-Br and Indazole-Cl repressed
IL-23p19 and IL-6 in primary mouse microglia cells (Figures
S1H and S1I). It was reported that IL-1b, but not IL-6, is required
for the differentiation of human Th17 cells (Acosta-Rodriguez
et al., 2007; Wilson et al., 2007). Therefore, we also tested
whether the Indazoles repressed these cytokines in human mi-
croglia cells. Indazoles significantly repressed the mRNA
expression of IL-1b (Figure 1G) and IL-23p19 (Figure 1H) to
a greater extent than 17b-estradiol. In contrast, 17b-estradiol,
but not Indazoles, suppressed expression of TGFb in human
primary microglia (Figure S1J). Next, we tested ERb-depend-
ency of Indazole-mediated repression of IL-1b, using siRNAs
specific for ERb and ERa. Transfection of siRNAs specifically
targeting ERb abolished Indazole-Cl-mediated repression of
IL-1b (Figure S1K-M). In contrast, transfection of siRNAs against
ERa did not show any reversal of Indazole-Cl-mediated repres-
sion. Thus, Indazole-Cl-mediated repression of proinflammatory
genes in human microglia cells is also mediated by ERb.
Finally, wemeasured cytokine secretion bymouse and human
microglia cells by ELISA. Consistent with mRNA data, the
production of IL-6 and IL-23 were strongly induced by LPS stim-
ulation, and both Indazole-Br and Indazole-Cl significantly in-
hibited their secretion (Figures 1I and 1J), with corresponding
effects on IL-1b in human microglia (Figure 1K). These data indi-
cate that, in contrast to 17b-estradiol, Indazole-Br and Indazole-
Cl act to strongly suppress the production of proinflammatory
mediators in response to LPS, including those required for the
differentiation and activation of Th17 T cells.Cell 145, 584–595, May 13, 2011 ª2011 Elsevier Inc. 585
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Figure 1. Indazoles Repress Inflammatory
Responses in Microglia
(A) Indazole-Br and Indazole-Cl inhibit LPS
induction of iNOSmRNA 6 hr after LPS stimulation
of murine BV2 microglia cells. *p < 0.01 compared
to EtOH sample.
(B) Inhibitory effects of Indazole-Cl on LPS induc-
tion of iNOS in BV2 cells are abolished by knock-
down of ERb expression. *p < 0.01 compared to
control siRNA transfected samples.
(C–F) Effects of Indazole-Br and Indazole-Cl on
LPS induction of IL-23p19 (C), IL-6 (D), IL-1b (E)
and TGFb (F) mRNAs in BV2 cells. *p < 0.01
compared to EtOH treated 1 hr LPS stimulated
sample, **p < 0.01 compared to EtOH treated 6 hr
LPS stimulated sample.
(G–H) Indazole-Br and Indazole-Cl inhibit LPS
induction of IL-1b (G) and IL-23p19 (H) mRNAs
(black bar) in human primary microglia cells. *p <
0.01 compared to 1 hr LPS + EtOH-stimulated
sample, *p < 0.01 compared to 6 hr LPS + EtOH-
stimulated sample.
(I–K) Indazole-Br and Indazole-Cl inhibit LPS-
induced secretion of mouse IL-6 (I), mouse IL-23
(J) and human IL-1b 24 hr after stimulation of
corresponding primary mouse and human micro-
glia cells as determined by ELISA. *p < 0.01
compared to EtOH treated sample. Error bars
represent SD. In-Br and In-Cl are Indazole-Br and
Indazole-Cl, respectively. E2 is 17b-estradiol. See
also Figure S1.A Subset of ERb-Specific Ligands Inhibit Inflammatory
Responses in Astrocytes
Astrocytes also contribute to inflammatory responses and have
been reported to be a major source of BAFF (also known as
BLyS/TNFSF13B) (Krumbholz et al., 2005), which supports the
survival of potential auto-reactive B cells (Mackay and Browning,
2002). Since both human and mouse primary astrocytes express
high levels of ERb (Figure S2A and B), we next examined whether
the Indazoles repressed inflammatory responses in these cells.
Activated mouse and human astrocytes upregulated mRNA
expression of BAFF when stimulated by IL-1b, consistent with
previous reports, and Indazole-Br and Indazole-Cl, but not
17b-estradiol, significantly repressed this response (Figures 2A
and 2D). Similarly, Indazole-Br and Indazole-Cl suppressed
IL1b-induced expression of IL-23p19 and iNOSmRNAs inmouse
and human astrocytes (Figures 2B, 2C, 2E, and 2F). Although, the586 Cell 145, 584–595, May 13, 2011 ª2011 Elsevier Inc.expression of ERa in astrocytes is signifi-
cantly lower than ERb, we confirmed that
Indazole-mediated repressionwas indeed
ERb-dependent by knockingdownERaor
ERb expression using specific siRNAs
(Figure S2C). As shown in Figure 2G,
knockdown of ERb expression, but
not ERa expression, reverted Indazole-
Cl-mediated repression of BAFF mRNA
expression. Notably, siRNA knockdown
of ERb resulted in a marked increase in
induced BAFF expression. Finally, theGreiss reaction was used to determine effects of ERb ligands on
IL-1b-induced NO production. Indazole-Br and Indazole-Cl, but
not 17b-estradiol, inhibited IL-1b-induced production of NO in
human astrocytes (Figure 2H).
Synthetic andEndogenousERbModulators Prevent EAE
in Mice
To determine whether Indazoles could inhibit inflammation in the
brain, we monitored the effect of Indazole-Cl treatment on the
expression of proinflammatory genes in the substantia nigra
following injection of LPS into the peritoneal cavity (Figure 3A),
which induces both systemic and CNS inflammation (Bhaskar
et al., 2010). Indazole-Cl treatment suppressed induction of
IL-6 in the substantia nigra (Figure 3A), but did not suppress
iNOS induction in the bone marrow (Figure S3A), consistent
with high expression of ERb in microglia and astrocytes, but
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Figure 2. Indazoles Repress Inflammatory
Responses of Astrocytes
(A–C) Indazole-Br and Indazole-Cl inhibit IL-
1b-dependent induction of BAFF (A), IL-23p19 (B)
and iNOS (C) mRNAs in primarymouse astrocytes.
*p < 0.01 compared to EtOH treated IL1b stimu-
lated sample, **p < 0.01 compared to EtOH treated
6 hr LPS stimulated sample.
(D–F) Indazole-Br and Indazole-Cl inhibit IL-
1b-dependent induction of BAFF (D), IL-23p19 (E),
and iNOS (F) mRNAs in primary human astrocytes.
**p < 0.01 compared to EtOH treated 6 hr IL-1b
stimulated sample. # p < 0.01 compared to EtOH
treated nonstimulated sample.
(G) siRNA-mediated knockdown of ERb in astro-
cytes results in exaggerated BAFF expression in
response to IL-1b and abolishes the inhibitory
effects of Indazole-Cl.
(H) Indazole-Br and Indazole-Cl inhibit IL1b-de-
pendent production of nitric oxide (NO) by human
primary astrocytes as determined by the Greiss
reaction. *p < 0.01 compared to EtOH treated and
IL-1b stimulated sample. Error bars represent SD.
See also Figure S2.low expression in myeloid cells. Based on the ability of Indazole-
Br and Indazole-Cl to repress induction of factors in microglia
that promote Th17 T cell differentiation and activation, and the
established roles of microglia in the onset of EAE (Heppner
et al., 2005), we also evaluated effects of Indazole-Cl on devel-
opment of EAE. Female C57BL/6 mice (WT mice) without
oophorectomy were immunized with MOG35-55 peptide in the
presence of complete Freund adjuvant and pertusis toxin,
following an aggressive protocol (Stromnes and Goverman,
2006). After about 3 weeks of immunization with peptide, mice
treated with ethanol (vehicle) showed severe signs of EAE. In
contrast, Indazole-Cl treated mice showed no obvious signs or
limited paralysis only in tails (Figure 3B). The therapeutic effect
of Indozole-Cl required ERb, as it had no effect on the severity
of EAE in ERb/ mice (Figure 3B). Consistent with in vitro data
(Figure 1 and Figure 2), Indazole-Cl treatment of WT EAE-in-
ducedmice resulted in the reduction of Th17 T cells (Figure S3B).
Although ERb/mice did not exhibit more severe disease than
WT mice in these studies, the aggressive immunization protocol
might have precluded measurement of a difference in sensitivity.
To address this possibility, a second series of studies was
performed using a less aggressive immunization protocol that
produced mild tail paralysis in WT animals. In these experiments,
ERb/ mice still developed severe disease, indicating that lossCell 145, 584–of ERb increases susceptibility to EAE
(Figure S3C). Finally, to test the potential
clinical utility of Indazole-Cl treatment,
studies were performed using the aggres-
sive immunization protocol in which treat-
ment was not initiated until after animals
exhibited signs of disease (approximate
clinical score of 1) (Figure 3C). Both
Indazole-Cl-treated and vehicle-treated
animals continued to worsen for the nextthree to fourdays.Thereafter, treatedanimalsexhibitedsignificant
improvement, while untreated animals developed increasingly
severedisease, indicating that Indazole-Clcanpromote resolution
of established inflammation after it has been established.
ADIOL Is an Endogenous ERb Ligand and Controls
Inflammation in Microglia
Although 17b-estradiol binds to ERb and stimulates its transcrip-
tional activities on positively regulated genes (Kuiper et al., 1996)
it was much less effective at inhibiting inflammatory responses
than Indazole-Br or Indazole-Cl. This observation raised the
questionofwhether endogenoussteroidsother than17b-estradiol
might act similarly to Indazole-Br or Indazole-Cl to effect ERb-me-
diated repressionof inflammatory responsegenes inmicrogliaand
astrocytes. Toaddress thisquestion,wescreenedapanel of natu-
rallyoccurringsteroids reported tobindERb (Kuiperetal., 1997) for
the ability to suppress induction of IL-6 in microglia upon LPS
stimulation (Figure 3D) as well as synthetic or plant plant-derived
steroids (Figure S3D). Although most of these molecules had no
activity, ADIOL (5-androstene-3b,17b-diol), the synthetic ligand
4-estren-17b-ol-3-one (19-nortestosterone) and the nonsteroidal
ligand coumestrol exerted substantial repressive effects, while
DHEA (5-androsten-3b-ol-17-one, dehydroepiandrosterone) and
5a-androstan-3b,17b-diol had weak activity.595, May 13, 2011 ª2011 Elsevier Inc. 587
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Figure 3. Indazole-Cl and ADIOL Exert Anti-
inflammatory Effects In Vivo and Inhibit EAE
Dependent on ERb
(A) Systemic administration of Indazole-Cl
(approximately 2.4 mmol/kg/day) blocks the ability
of LPS injection (10 mg/kg) to induce IL-6
expression in the substantia nigra (n = 4/group).
Data are representative of three independent
experiments.
(B). Indazole-Cl (2.4 mmol/kg/day) inhibits devel-
opment of EAE in wild-type female mice, but not in
ERb knockout female mice. Clinical scores are
indicated for age matched wild-type mice treated
with EtOH (n = 24, black dashed line), wild-type
mice treated with Indazole-Cl treated (n = 24,
black solid line), ERb/ mice treated with EtOH
(n = 8, red dashed line), and ERb/ mice treated
with Indazole-Cl (n = 8, red solid line) (0 = no
evidence of disease, 4 = moribund. See Extended
Experimental Procedures for immunization
protocol and scoring system). Data are represen-
tative of three independent experiments.
(C) Indazole–Cl induces partial remission of es-
tablished EAE. EAE was induced and scored as in
B, but Indazole-Cl (n = 8) or EtOH vehicle (n = 8)
treatments were not initiated until mice exhibited
a clinical score of 1 (day 10). Data are repre-
sentative of two independent experiments.
(D). A screen of endogenous steroids identifies
ADIOL as a suppressor LPS induction of IL-6 in
BV2 cells. *p < 0.01 compared to EtOH treated 6 hr
LPS stimulated sample.
(E). Structure of ADIOL.
(F). Systemic administration of ADIOL (2.4 mmol/
kg/day) blocks the ability of LPS injection (10 mg/
kg) to induce IL-6 expression in the substantia ni-
gra (n = 5/group). Data are representative of two
independent experiments.
(G). ADIOL (2.4 mmol/kg/day) inhibits development
of EAE in wild-type female mice, but not in ERb
knockout female mice. Age matched wild-type
mice treated with EtOH (n = 8, black dashed line),
wild-type mice treated with ADIOL (n = 8, black
solid line), ERb/ mice treated with EtOH (n = 8,
red dashed line), and ERb/ mice treated with
ADIOL (n = 8, red solid line) were scored for clinical
severity as in (B).
Data are representative of three independent
experiments. Error bars represent SD. See also
Figure S3.We focused our attention on ADIOL (Figure 3E) because it can
be generated from its precursor DHEA in microglia by reduction
of the 17 keto group (Jellinck et al., 2007). In addition to sup-
pressing activation of IL-6, ADIOL also inhibited the expression
of IL-1b upon LPS stimulation of human microglia (Figure S3E),
and the expression of iNOS mRNA in mouse astrocytes when
cells were stimulated by IL-1b (Figure S3F). In microglia, ADIOL
repressed induction of IL-6 mRNA transcription with an IC50
of 30–100 nM (Figure S3G). ADIOL-mediated repression of
inflammation was dependent on ERb, since siRNA against ERb
abolished the repression of IL-23p19 in microglia (Figure S3H).
ADIOL also repressed the expression of IL-6 in the substantia
nigra following LPS injection into peritoneal cavity, indicating588 Cell 145, 584–595, May 13, 2011 ª2011 Elsevier Inc.that ADIOL can repress microglia-mediated inflammation
in vivo (Figure 3F). Next we evaluated the ability of ADIOL to
repress the signs of EAE. Although less efficacious than Inda-
zole-Cl, ADIOL also suppressed signs of EAE in an ERb-depend-
ent manner (Figure 3G). These findings suggest that ADIOL is
a steroid with ERb-modulatory activities similar to those of Inda-
zole-Cl and Indazole-Br.
Regulated Production of ADIOL by HSD17B14
The conversion of DHEA to ADIOL requires the enzymatic
activities of 17b-hydroxysteroid dehydrogenases (17b-HSD,
HSD17B) (Figure 4A) (Moeller and Adamski, 2009). HSD17B1
was previously reported to mediate the conversion of DHEA to
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Figure 4. HSD17B14 Mediates ADIOL Generation
in BV2 Microglia Cells and Regulates Inflamma-
tory Responses
(A) A partial scheme of the biosynthesis and metabolism
of ADIOL.
(B) HSD17B14 mediates conversion of DHEA to ADIOL.
COS-1 cells were transfected with the indicated expres-
sion vectors, using HSD17B1 as a positive control, and
the products of DHEA conversion were monitored by gas
chromatography at 0, 1 and 6 hr. Retention times for
DHEA and ADIOL standards are indicated.
(C) Knockdown of HSD17B14 in BV2 cells by stable
transduction with a lentiviral vector directing expression
of a specific shRNA inhibits conversion of DHEA to
ADIOL. ADIOL levels in media were quantified 24 hr after
addition of DHEA.
(D). Stable knockdown of HSD17B14 using two different
shRNAs blocks the ability of DHEA, but not ADIOL or In-
dazole-Cl, to suppress LPS induction of IL-6 mRNA in
BV2 cells. Cells were pretreated with the indicated
ligands for 1 hr except for DHEA, which was added 6 hr
prior to LPS stimulation. *p < 0.01 compared to EtOH
treated and LPS stimulated sample. Error bars represent
SD. See also Figure S4.ADIOL (Lin et al., 2006). However, there are at least 14 different
members of the 17b-HSD family identified in humans and mice,
and some of them could also potentially convert DHEA to ADIOL
(Moeller andAdamski, 2009). ADIOL is converted by 3b-hydroxy-
steroid dehydrogenase/D5, D4 isomerase (3b-HSD, HSD3B) to
testosterone, and finally to estradiol by aromatase (Figure 4A)Cell 145(Simard et al., 2005). Mouse and human micro-
glia express most of the 17b-HSDs to variable
extents (Figures S4A and S4B, respectively).
Among these, HSD17B14 is highly expressed
and is located on human chromosome 19q13,
which has been identified as an MS susceptible
locus (Bonetti et al., 2009; Wise et al., 1999).
17b-HSD type 14 (HSD17B14) is a newly iden-
tified member of the 17b-HSD family initially
shown to covert estradiol to estrone (Lukacik
et al., 2007). To investigate whether HSD17B14
is also able to convert DHEA to ADIOL, COS-1
cells that do not exhibit endogenous activity to
convert DHEA to ADIOL (Figure 4B, left column)
were transiently transfected with expression
vectors for HSD17B1 or HSD17B14. Then cells
were pulsed with DHEA and conversion to
metabolites was monitored over time by gas
chromatography (GC). Expression of HSD17B1
efficiently catalyzed conversion of DHEA to
a product that exhibited an identical retention
time to that of an ADIOL standard, consistent
with the previously established enzymatic
activity of HSD17B1 (Figure 4B, middle panel).
As shown in Figure 4B (right column), expression
of HSD17B14 at similar proteins levels (Fig-
ure S4C) generated a product with an identical
retention time with similar efficiency. Impor-tantly, the supernatants from HSD17B1 and B14-expressing
cells, but not frommock-transfected cells, repressed the expres-
sion of IL-6 upon LPS stimulation in BV2 microglia cells in
a manner similar to that of ADIOL (Figure S4D). Next, to investi-
gate whether HSD17B14 might contribute to conversion of
DHEA into ADIOL in microglia cells, we generated stable BV2, 584–595, May 13, 2011 ª2011 Elsevier Inc. 589
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Figure 5. HSD17B Expression Is Regulated
by Pro- and Anti-inflammatory Stimuli
(A) Knockdown of ERb and HSD17B14, but not
HSD17B1, results in exaggerated and prolonged
induction of IL-23p19 mRNA in LPS-treated BV2
cells.
(B and C) LPS treatment of primary mouse (B) and
human (C)microglia cells results in downregulation
of HSD17B14 expression. *p < 0.01 and **p < 0.001
compared to nonstimulated sample.
(D). LPS treatment of BV2 cells suppresses
production of ADIOL. *p < 0.001 compared to
nonstimulated sample.
(E and F) IL-10 induces expression of HSD17B14
mRNA in primary mouse (E) and human (F) micro-
glia. *p < 0.01 compared to nonstimulated sample.
(G). 17b estradiol (E2) inhibits ADIOL repression of
IL-6 in LPS-treated BV2 cells. *p < 0.01 compared
to ADIOL + LPS alone. In all panels, error bars
represent SD. See also Figure S5.microglia cell lines expressing specific short hairpin RNAs
(shRNAs) against HSD17B14 (shHSD17B14), HSD17B1
(shHSD17B1) or scramble control (shCtrl) using lentivirus vectors
(Figure S4E). Knockdown of HSD17B14, but not HSD17B1,
significantly reduced the conversion of DHEA to ADIOL (Fig-
ure 4C). In addition, knockdown of HSD17B14 resulted in greatly
exaggerated responses to LPS and abolished the ability of DHEA
to suppress LPS induction of IL-6mRNA (Figure 4D). In contrast,
ADIOL and Indazole-Cl suppressed LPS induction of IL-6 in
all three cell lines. Collectively, these findings suggest that
HSD17B14 can efficiently catalyze the production of ADIOL
from DHEA in microglia cells.
To further investigate the role of HSD17B14 in controlling ERb
activity in microglia, we compared the consequences of knock-
ing down HSD17B14, HSD17B1 and ERb on the magnitude590 Cell 145, 584–595, May 13, 2011 ª2011 Elsevier Inc.and duration of the response to LPS.
Knockdown of ERb and HSD17B14, but
not HSD17B1, increased and prolonged
the induction of IL-23p19 (Figure 5A)
and IL-6 (Figure S5A) mRNAs. Notably,
HSD17B14mRNA expression was down-
regulated in mouse and human microglia
by LPS treatment (Figures 5B and 5C).
Consistent with this, ADIOL conversion
was decreased following LPS stimulation
of microglia cells (Figure 5D). Expression
of HSD17B14 was also downregulated
by IL-1b in mouse and human astrocytes
(Figures S5C and S5D, respectively).
Conversely, LPS induced expression of
the major 3b-HSDs expressed in mouse
and human microglia (Figures S5D and
S5E). Interestingly, the anti-inflammatory
cytokine IL-10 upregulated the expres-
sion of HSD17B14 in mouse and human
microglia (Figures 5E and 5F).
The observation that 17b-estradiol
inefficiently induced anti-inflammatoryactivities of ERb in microglia and astrocytes, but binds to ERb
with a higher affinity than ADIOL (Kuiper et al., 1997) raised the
possibility that it could antagonize ERb-mediated repression of
inflammatory response genes. Consistent with this possibility,
17b-estradiol inhibited ADIOL suppression of IL-6 induction,
with an IC50 value of0.1 mM, in accord with the relative affinities
of 17b-estradiol and ADIOL for ERb (Figure 5G).
ERb-Mediated Repression Is Initiated by Tethering
to cFos
Amajor question raised by these observationswas themolecular
basis for differential activities of 17b-estradiol and the Indazoles
and ADIOL. Nuclear receptors can act as transcriptional repres-
sors by direct interactions with specific DNA sequences in target
genes or by transrepression mechanisms involving tethering to
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Figure 6. ERb Tethers to cFos in a Protein
Kinase A-Dependent Manner
(A) Sequence-specific DNA binding is not required
for ERb-mediated repression. RAW264.7 cells
were transfected with a vector directing expres-
sion of a DBD mutant of ERb and a specific siRNA
directed against ERa. Cells were stimulated with
LPS in the presence of the indicated ligands and
iNOS-promoter activity was measured by lucif-
erase-reporter assay. *p < 0.01 compared to EtOH
treated sample.
(B) LPS stimulates the interaction of ERbwith cFos
in BV2 cells. Lysates of BV2 cells stimulated with
LPS for the indicated times were immunoprecipi-
tated with anti-ERb antibody, and western blots
were developed with anti-cFos antibody.
(C) ERb is recruited to the IL-23p19 promoter
coincident with cFos as detected by ChIP assay.
(D) LPS treatment of BV2 cells induces phos-
phorylation of the protein kinase A (PKA) substrate
S362 of cFos.
(E) Protein kinase A is required for Indazole-
Cldependent repression. Expression of IL-6
mRNA 6hr after LPS stimulation was determined in
BV2 cells stably expressing a control shRNA or
shRNAs directed against the a and b PKA catalytic
subunits. Error bars represent SD. *p < 0.01.
(F) Knockdown of the PKA-a and b catalytic
subunits abolishes LPS-induced interaction of
ERb with cFos as determined by coimmunopre-
cipitation assay as in (D).
(G) Phosphorylation of cFos at S362 is required for
LPS-induced interaction with ERb. Lentivirus
carrying HA-tagged wild-type (WT), S352A and
S362E mutant cFos were infected into BV2 cells.
Cells were stimulated with LPS for 30 min and
whole cell extracts were analyzed by immuno-
precipitation with a -ERb antibody and western
blotting for HA. See also Figure S6.other transcription factors that are specifically bound to target
gene promoters (Glass and Saijo, 2010). To test which of these
was used by ERb to suppress inflammatory response genes,
we mutated the DNA binding domain (DBD) of ERb so that it
could not bind to estrogen responsive element (ERE) sequences.
RAW264.7 cells were transfected with wild-type ERb or DBD
mutant expression plasmids together with siRNAs directed
against ERa to prevent any spurious effects of ERa. The DBD
mutant of ERbwas unable to activate an ERE-luciferase reporter
gene as expected (Figure S6A), but was able to repress induction
of iNOS-luciferase by LPS (Figure 6A), consistent with a transre-
pression mechanism. Next, we looked for potential transcription
factors that ERb could tether to on target gene promoters.
Among the factors evaluated, ERb was found to coimmunopre-
cipitate with cFos upon LPS stimulation in BV2 cells (Figure 6B).
Chromatin immunoprecipitation (ChIP) assays demonstrated
that ERb and cFos were recruited to the IL-23p19 promoter in
BV2 cells in response to LPS (Figure 6C). ERb was not recruited
to the promoter in cFos knockdown BV2 cells (Figure S6B),
consistent with a tethering-dependent mechanism.
We next investigated specific signals thatmight be required for
inducing this interaction. cFos is known to be phosphorylated by
several kinases such as ERK, RSK and IKKb and protein kinaseA (PKA) (Koga et al., 2009; Piechaczyk and Blanchard, 1994).
Surprisingly, LPS treatmentofmicroglia inducedphosphorylation
of cFos at sites that could be detectedwith an anti-phospho-PKA
substrate antibody (Figure 6D), implicating phosphorylation by
PKA. Consistent with this observation, LPS stimulation induced
the activation of PKA in microglia cells (Figure S6C). IL-1b and
CpG DNA also activated PKA, while polyI:C did not (Figure S6E),
suggesting involvement of the MyD88 pathway. To investigate
whether PKA activity was important for ERb-mediated repres-
sion, we established microglia cell lines in which shRNAs were
used to knock down expression of the two catalytic subunits of
PKA, Ca andCb (Wall et al., 2009). As shown in Figure 6E, knock-
down of the catalytic subunits of PKA abolished Indazole-medi-
ated repression of IL-6. Similarly, the stimulation-dependent
binding of cFos and ERbwas abolished in these cells (Figure 6F).
Finally,we identified serine362 (S362) as themain residue in cFos
targeted by PKA-phosphorylation and mutated this residue into
alanine to prevent phosphorylation (S362A) or to glutamate to
mimic constitutive phosphorylation (S362E). The cFos S362A
mutant exhibited impaired stimulation-dependent binding to
ERb, while the S362E mutant exhibited constitutive interaction
(Figure 6G). These results suggest that ERb-mediated repression
of proinflammatorymediators inmicroglia is initiated by tetheringCell 145, 584–595, May 13, 2011 ª2011 Elsevier Inc. 591
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Figure 7. CtBP Is a Ligand-Specific Corepressor
of ERb
(A) BV2 cells were transfected with specific siRNAs
against CtBP1 (siCtBP1), CtBP2 (siCtBP2) or control
(siCtrl), and expression of IL-23p19 mRNA was deter-
mined 1hr after LPS stimulation. *p < 0.01 compared to
siCtrl samples.
(B) CtBP1/2 are recruited to the IL-23p19 promoter in
response to the combination of Indazole-Cl plus LPS
(circle, black solid line) as determined by ChIP assay. For
Indazole-Cl plus LPS treatment conditions, cells were
pretreated with Indazole-Cl for 1hr followed by LPS for the
indicated times.
(C) Recruitment of CtBP to the IL-23p19 promoter requires
ERb. BV2 cells transduced with shRNA against ERb
(shERb, solid line) or control (shCtrl, dash line) were pre-
treated with Indazole-Cl for 1hr followed by LPS stimula-
tion for the indicated times prior to ChIP assay using
anti-CtBP. Data are shown as % input.
(D) Ligand dependent binding of CtBP and ERb. BV2 cells
were stimulated with LPS, 17b-estradiol (E2), Indazole-Cl
and ADIOL for 30 min. Lysates were immunoprecipitated
with anti-ERb antibody. IP samples and inputs were
developed with anti-CtBP antibody.
(E). Model for ERb-mediated repression. See Discussion
for details. See also Figure S7.of ERb to cFos in a PKA-mediated phosphorylation-dependent
manner.
Ligand-Specific Recruitment of CtBP to ERb Mediates
Transrepression
Transrepression functions of nuclear receptors have previously
been documented to involve prevention of corepressor removal
or corepressor recruitment (Glass and Saijo, 2010). Therefore,
we next performed an siRNA screen to search for corepressors
that might be required for ERb transrepression activity in micro-
glia cells. In this screen, siRNAs directed against either
C-terminal binding protein (CtBP)1 or 2 were found to revert In-
dazole-mediated repression of IL-23p19 (Figure 7A) and
ADIOL-mediated repression of IL-6 (Figure S7A). Thus, we spec-
ulated that ERb recruits CtBP corepressor complexes upon
ligand treatment. To confirm whether CtBP was recruited to
the target gene promoters, we performed ChIP assay at the592 Cell 145, 584–595, May 13, 2011 ª2011 Elsevier Inc.IL-23p19 and IL-6 promoter. LPS alone or Inda-
zole alone did not recruit CtBP at the promoter
region, but both LPS and Indazole (Figure 7B
and Figure S7B) or ADIOL (Figures S7C and
S7D) induced the recruitment of CtBP at the
promoter region. To confirm whether ERb is
required for the recruitment of CtBP to the
promoter, we performedChIP assay in BV2 cells
infected the lentivirus carrying specific shRNA
against ERb (shERb). As shown in Figure 7C,
the recruitment of CtBP was abolished in shERb
cells upon LPS and Indazole treatment, sug-
gesting that ERb is acting as a beacon for CtBP.
Importantly, CtBP could be coimmunopreci-
pitated with ERb in microglia cells that werestimulated by Indazole-Cl and ADIOL, which induced the repres-
sive function of ERb, but not by 17b-estradiol, which did not stim-
ulate transrepression activity of ERb in microglia (Figure 7D).
Although LPS stimulation was required to promote interaction
of ERb with cFos, it was not required for the interaction between
ERb and CtBP in microglia (Figure 7D). These observations
suggest that the selective ability of Indazole-Cl/Br and ADIOL
to recruit CtBP complexes to ERb provides a molecular explana-
tion for their differential effects on inflammatory gene expression.
DISCUSSION
ERa and ERb activate target genes in response to 17b-estradiol
and both are considered to be physiologic estrogen receptors
(Minutolo et al., 2009; Pettersson and Gustafsson, 2001).
Although ERa and ERb have highly conserved DNA binding
domains, recent studies have shown that there are significant
differences in the chromatin binding sites that they occupy upon
stimulation by 17b-estradiol or other hormonal ligands and the
genes that they regulated (Chang et al., 2008; Grober et al.,
2011). In addition, variation in their respective ligand-binding
cavities confers overlapping but distinct ligand-binding proper-
ties (Kuiper et al., 1997; Minutolo et al., 2009). These differences
have been exploited for the development of numerous synthetic
ligands that exhibit marked preferences for binding to ERa or
ERb (Minutolo et al., 2009). In most cases, functional evaluation
of these ligands has been carried out to characterize their ability
to positively regulate estrogen-responsive reporter genes
(Meyers et al., 2001; Stauffer et al., 2000) or endogenous genes
(Chang et al., 2008). The present studies are based on the seren-
dipitous observation that two ERb-specific ligands based on
a halogen-substituted phenyl-2H-indazole core (De Angelis
et al., 2005) potently suppressed transcriptional activation of
TLR4-responsive genes in microglia, while 17b-estradiol and,
in particular, a number of other ERb-selective ligands did not.
Notably, Indazole-Br and Indazole-Cl suppressed production
of cytokines by activated microglia and astrocytes that promote
Th17 cell differentiation and activation, and Indazole-Cl potently
inhibited signs of EAE in mice in an ERb-dependent manner and
reversed established disease.
These findings raised the question of whether Indozole-Br and
Indazole-Cl might be mimicking the activities of endogenous
sterols other than 17b-estradiol that function to regulate the
transrepression activities of ERb. Studies of endogenous
steroids that are known to bind to ERb (Kuiper et al., 1997) re-
sulted in the identification of ADIOL and a small set of other natu-
rally occurring and synthetic steroids as also being able to
repress induction of proinflammatory cytokines in microglia,
raising the possibility of ERb-dependent anti-inflammatory roles
of thesemolecules in vivo. Potential functional roles of ADIOL are
of particular interest because of extensive prior work document-
ing its biosynthesis in microglia (Jellinck et al., 2007) and linkage
of genetic variation in the vicinity of the 17b-HSD type 14 locus to
risk of Multiple Sclerosis (Bonetti et al., 2009; Wise et al., 1999).
A working model for how ERb could act as a transcriptional
repressor is illustrated in Figure 7E. First, inflammatory stimuli
such as LPS induce binding of cJun/cFos AP-1 heterodimers
to inflammatory responsive genes. PKA is coordinately activated
in aMyD88-dependent manner and induces the phosphorylation
of cFos, providing a docking site for ERb. Binding of Indazole-
Br/Cl or ADIOL to ERb induces interaction of the CtBP-
repressor, resulting in transcriptional repression. This proposed
transrepression mechanism is functionally analogous to transre-
pression mechanisms utilized by the glucocorticoid receptor
(Rogatsky et al., 2002) and Nurr1 (Saijo et al., 2009) to recruit
GRIP and CoREST corepressor complexes, respectively, to
transcriptionally active promoters. Thus, the ERb pathway func-
tions as a negative feedback mechanism to attenuate transcrip-
tion from active promoters.
CtBP complexes can also be used to mediate active repres-
sion by ERa at a subset of estrogen response elements (Stossi
et al., 2009). A key question is therefore to understand the mech-
anisms and specificity of recruitment of the CtBP complex. The
present studies indicate that Indazole-Br/Cl and ADIOL function
as selective ERbmodulators that effectively promote interactionwith this complex. The inability of 17b-estradiol to induce CtBP
interaction therefore provides a molecular explanation for the
differential effects of Indazoles and ADIOL versus 17b-estradiol
as inhibitors of inflammatory response genes in microglia. It
will be of considerable interest to define the structural differ-
ences imposed by these ligands on the ERb ligand domain and
how these differences are ultimately interpreted by components
of the CtBP complex. CtBP frequently interacts with target
proteins through a PXDLS motif (Schaeper et al., 1998), but
ERb does not have this motif. Therefore, alternative linker
proteins are likely to be involved in bridging ERb and CtBP in
ligand-dependent manner, possibly involving post-translational
modifications. Further studies will be required to establish the
precise mechanisms of interaction.
Overall, our data suggest that in addition to being a receptor for
17b-estradiol, ERb is a physiologic receptor for ADIOL that is
produced in an autocrine manner by microglia (Jellinck et al.,
2007), and potentially astrocytes. Although, the concentration
of ADIOL in the brain is not clear at this moment, knockdown of
HSD17B14 in microglia cells cultured in 10% serum resulted in
an exaggerated inflammatory response. This result suggests
that the concentrations of serum-derived DHEA provide
substrate for synthesis of sufficient ADIOL to suppress inflamma-
tory responses. The findings that HSD17B14 and HSD3Bs are
reciprocally regulated by LPS and that HSD17B14 is positively
regulated by the anti-inflammatory cytokine IL-10 suggests that
in the setting of acute infection or injury, the ADIOL pathway is
rapidly downregulated to allow an effective inflammatory
response to occur. Upon eradication of the inciting stimulus,
anti-inflammatory cytokines such as IL-10 induce expression of
HSD17B14, which by activating the ERb/CtBP pathway, could
promote resolution of inflammation and re-establishment of the
de-activated phenotypes of microglia and astrocytes, in concert
with other resolution pathways. The finding that 17b-estradiol
can antagonize the anti-inflammatory activities of ADIOL
provides another level by which the ADIOL pathway might be
controlled, and could help explain some of the complexity of
estrogen activity in the brain and the increased susceptibility of
females to Multiple Sclerosis.
The ability of Indozole-Cl to induce remission of EAE after clin-
ical signs have developed suggests new points of therapeutic
intervention in neurodegenerative diseases in which inflamma-
tion plays a pathogenic role. Prior studies of the ERb-selective
ligand DPN in EAE demonstrated limited benefit that was unre-
lated to inflammation (Tiwari-Woodruff et al., 2007), consistent
with our finding that it does not promote entry of ERb into the
CtBP-dependent transrepression pathway. This, together with
our finding that DPN and another ERb-selective ligand, ERB-
041, were inactive in repressing activation of inflammatory
response genes in microglia that were inhibited by Indazoles,
indicates that ligands that are ERb-selective but have somewhat
different structures can have surprisingly different activities.
Although not widely documented, this compound-specific
activity of different ERb-selective ligands appears to be an
emerging trend (Minutolo et al., 2009). Therefore, the develop-
ment of ERb-specific ligands that are optimized for this activity
might be of therapeutic benefit in diseases driven by dysfunction
of the innate and adaptive immune systems.Cell 145, 584–595, May 13, 2011 ª2011 Elsevier Inc. 593
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice were obtained from Charles River and ERb/ mice were
purchased from Jackson laboratory. All animal housing and experiments
were approved by IACUC at UCSD.
Cell Culture
Primary human microglia and astrocytes were obtained from Clonexpress and
Sciencell, respectively. COS-1 cells were purchased from ATCC. Primary
mouse microglia and astrocytes were obtained and cultured as described
before (Saijo et al., 2009). To treat the cells with various ERb ligands, cells
were cultured in DMEM without Phenol-red (Invitrogen) supplemented with
10% Charcoal/Dextran-stripped FBS (Hyclone) for 24 hr in prior to the
pretreatment. Then, cells were incubated with the indicated ligands at the final
concentration of 1 mM unless otherwise noted for 1 hr followed by 0.1 mg/ml
LPS (E. coli 0111:B4, Sigma) to microglia or 10ng/ml IL-1b (R & D system) to
astrocytes for indicated time. See Extended Experimental Procedures for
other cells.
Reagents
All smart-pool siRNAs and GIPZ or pLKO.1 shRNA containing lentivirus were
purchased from Dharmacon and OpenBiosystems, respectively. Retrovirus
carrying shRNA against the PKA a and b catalytic subunits was kindly provided
by Mel Simon. Commercially available ERb ligands were purchased from
Steraloids.
Chromatin Immunoprecipitation Assays
2 3 107 BV2 cells were used for ChIP as described before (Saijo et al., 2009).
Anti-ERb (L-20 and H-150), anti-cFos (H-125 and 4) and anti-CtBP1/2 (E-12)
were purchased from Santa Cruz biotechnology.
RNA Isolation and Quantitative PCR
Total RNAwas isolated by RNAeasy kit (QIAGEN) from cells. Onemicrogram of
total RNA was used for cDNA synthesis using Superscript III (Invitrogen), and
quantitative PCRwas performed with SYBR-GreenER (Invitrogen) detected by
7300 Real Time PCR System (ABI). The sequences of qPCR primers used for
mRNA quantification in this study were obtained from PrimerBank (Spandidos
et al., 2010).
Experimental Autoimmune Encephalomyelitis
Osmotic pumps (Alzet) with ligands or vehicle were implanted under the skin
2 days before EAE induction or after the clinical score developed at 1.
8–12 weeks age-matched mice were used for the experiment based on the
standard protocol (Stromnes and Goverman, 2006). See Extended Experi-
mental Procedures for detailed protocols.
Gas Chromatography
For GC determination, steroids were extracted from 1ml of media and 25 mg of
androsterone (Steraloids) added as an internal standard using the method by
Gottfried-Blackmore et al. with minor modifications (Gottfried-Blackmore
et al., 2008). Samples were loaded onto a Shimadzu GC-2014 gas chromato-
gram using a 30m3 0.25mm (i.d.) ZB-5HT inferno capillary column (film thick-
ness 0.2 mm) (Phenomenex). See Extended Experimental Procedures for
detailed protocols.
Statistical Analyses
Standard deviation (SD), two-tail Student’s t test and ANOVA were performed
with the Prism 5 program. p < 0.01 was considered significant. All data are pre-
sented as mean ± SD.
SUPPLEMENTAL INFORMATION
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